Agios Pharmaceuticals (NASDAQ:AGIO) Upgraded at Zacks Research

Agios Pharmaceuticals (NASDAQ:AGIO) was upgraded by stock analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a report released on Tuesday,Zacks.com reports.

Several other brokerages have also issued reports on AGIO. Scotiabank decreased their price target on shares of Agios Pharmaceuticals from $71.00 to $65.00 and set a “sector outperform” rating for the company in a research note on Monday, July 28th. Weiss Ratings restated a “hold (c-)” rating on shares of Agios Pharmaceuticals in a research note on Wednesday, October 8th. HC Wainwright reiterated a “buy” rating and set a $56.00 price objective on shares of Agios Pharmaceuticals in a research report on Thursday, September 4th. Finally, Bank of America cut their target price on shares of Agios Pharmaceuticals from $52.00 to $51.00 and set a “buy” rating for the company in a report on Tuesday, July 22nd. Five analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $57.25.

Agios Pharmaceuticals Price Performance

AGIO stock opened at $40.51 on Tuesday. Agios Pharmaceuticals has a one year low of $23.42 and a one year high of $62.58. The stock has a market cap of $2.36 billion, a PE ratio of -5.79 and a beta of 0.89. The firm has a 50 day simple moving average of $39.67 and a two-hundred day simple moving average of $36.09.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported ($1.78) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.93) by $0.15. Agios Pharmaceuticals had a negative net margin of 895.86% and a negative return on equity of 28.35%. The company had revenue of $12.90 million during the quarter, compared to analysts’ expectations of $10.49 million. During the same quarter in the prior year, the company earned $16.22 EPS. The firm’s revenue was up 43.3% on a year-over-year basis. On average, research analysts expect that Agios Pharmaceuticals will post -6.85 EPS for the current fiscal year.

Insider Activity at Agios Pharmaceuticals

In other news, insider Sarah Gheuens sold 3,302 shares of the business’s stock in a transaction on Monday, October 27th. The shares were sold at an average price of $43.92, for a total transaction of $145,023.84. Following the completion of the sale, the insider directly owned 61,727 shares of the company’s stock, valued at approximately $2,711,049.84. The trade was a 5.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Brian Goff sold 11,085 shares of the business’s stock in a transaction on Friday, August 8th. The shares were sold at an average price of $36.67, for a total transaction of $406,486.95. Following the sale, the chief executive officer directly owned 123,528 shares of the company’s stock, valued at $4,529,771.76. This represents a 8.23% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 26,984 shares of company stock valued at $1,017,811 over the last ninety days. Company insiders own 4.30% of the company’s stock.

Institutional Trading of Agios Pharmaceuticals

A number of large investors have recently made changes to their positions in AGIO. NewEdge Advisors LLC bought a new stake in shares of Agios Pharmaceuticals in the first quarter valued at about $40,000. First Horizon Corp bought a new stake in shares of Agios Pharmaceuticals in the third quarter valued at about $45,000. CWM LLC raised its holdings in shares of Agios Pharmaceuticals by 150.2% in the first quarter. CWM LLC now owns 1,659 shares of the biopharmaceutical company’s stock valued at $49,000 after acquiring an additional 996 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Agios Pharmaceuticals by 16.7% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,237 shares of the biopharmaceutical company’s stock valued at $74,000 after acquiring an additional 320 shares in the last quarter. Finally, PNC Financial Services Group Inc. raised its holdings in shares of Agios Pharmaceuticals by 16.2% in the first quarter. PNC Financial Services Group Inc. now owns 3,582 shares of the biopharmaceutical company’s stock valued at $105,000 after acquiring an additional 499 shares in the last quarter.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.